

1 Jason Choy
2 Jason.Choy@wilmerhale.com
3 WILMER CUTLER PICKERING
4 HALE AND DORR LLP
5 350 South Grand Avenue, Suite 2400
6 Los Angeles, CA 90071
7 Telephone: +1 213 443 5334
8 Facsimile: +1 213 443 5400

9 Robert J. Gunther Jr.
10 (*pro hac vice to be filed*)
11 Robert.Gunther@wilmerhale.com
12 WILMER CUTLER PICKERING
13 HALE AND DORR LLP
14 7 World Trade Center
15 250 Greenwich Street
16 New York, NY 10007
17 Telephone: +1 212 230 8830
18 Facsimile: +1 212 230 8888

19 Attorneys for Plaintiff

20 **UNITED STATES DISTRICT COURT**
21 **SOUTHERN DISTRICT OF CALIFORNIA**

22 Genentech, Inc.,
23
24 Plaintiff,
25
26 v.
27 Tanvex BioPharma USA, Inc., Tanvex
28 BioPharma, Inc., Tanvex Biologics, Inc., and
Tanvex Biologics Corporation,
Defendants.

Case No. '22CV0809 RBM JLB

COMPLAINT

Demand for Jury Trial

1 For its Complaint against Defendants Tanvex BioPharma, Inc., Tanvex
2 BioPharma USA, Inc., Tanvex Biologics, Inc., and Tanvex Biologics
3 Corporation (collectively, “Tanvex”), Plaintiff Genentech, Inc. (“Genentech”)
4 alleges as follows:

5 **NATURE OF THE ACTION**

6 1. This is an action for patent infringement arising under the patent laws
7 of the United States, Title 35, United States Code, including 35 U.S.C. §
8 271(e)(2)(C), which was enacted in 2010 as part of the Biologics Price
9 Competition and Innovation Act of 2009 (“the BPCIA”), Pub. L. No. 111-148,
10 §§ 7001-7003, 124 Stat. 119, 804-21 (2010) (amending, inter alia, 35 U.S.C. §
11 271 and 42 U.S.C. § 262). Genentech asserts infringement of three patents in
12 this lawsuit: U.S. Patent No. 10,662,237, U.S. Patent No. 10,808,037, U.S.
13 Patent No. 8,574,869 (collectively, the “Patents-in-Suit”). *See* Exhibits 1-3. The
14 BPCIA provides a pathway for resolving patent disputes relating to biosimilar
15 products.

16 2. Tanvex is seeking FDA approval of a biosimilar version of
17 Genentech’s blockbuster antibody treatment for breast and gastric cancer called
18 Herceptin®. Tanvex’s proposed biosimilar product is called TX05. Upon
19 information and belief, Tanvex will be engaged in the manufacture, marketing,
20 and distribution of TX05 in the United States upon FDA approval.

21 3. As described further below, the parties exchanged information under
22 the BPCIA and agreed upon three patents to litigate with respect to Tanvex’s
23 abbreviated biologic license agreement (“aBLA”) submission for TX05.
24 Genentech thus brings this action for infringement of three patents pursuant to
25 35 U.S.C. § 271(e)(2) based upon Tanvex’s submission of its aBLA for TX05.
26 Genentech also seeks a declaratory judgment that the manufacture, use, offer to
27 sell, sale, or importation into the United States of Tanvex’s biosimilar product
28

1 would infringe the Patents-in-Suit. In the event that Tanvex imports or launches
2 its biosimilar product and/or otherwise practices the patented inventions in the
3 United States prior to the expiration of those patents, Genentech also seeks
4 monetary damages, including lost profits, and any further relief as this Court
5 may deem just and proper.

6 **THE PARTIES**

7 4. Plaintiff Genentech is a corporation organized and existing under the
8 laws of the State of Delaware with its corporate headquarters at 1 DNA Way,
9 South San Francisco, CA 94080. The company is dedicated to discovering,
10 developing, and commercializing medicines to treat patients with debilitating
11 and life-threatening diseases. Genentech developed and markets Herceptin® as
12 an antibody therapy for breast and gastric cancer.

13 5. Upon information and belief, Defendant Tanvex BioPharma USA,
14 Inc. is a corporation organized and existing under the laws of the State of
15 California, with its principal place of business in San Diego, California at 10394
16 Pacific Center Court, San Diego, CA 92121. Tanvex BioPharma USA, Inc. filed
17 the aBLA for Tanvex's TX05, which is a proposed biosimilar product to
18 Genentech's Herceptin®. Upon information and belief, Tanvex BioPharma
19 USA, Inc., developed TX05 and will manufacture TX05, import TX05 into the
20 United States, and market and distribute TX05 in California and throughout the
21 United States.

22 6. Upon information and belief, Tanvex BioPharma, Inc. is a
23 corporation organized and existing under the laws of the Cayman Islands, with
24 its principal place of business in Taipei City 106, Taiwan at 13F.-1, No. 376,
25 Sec. 4, Ren'ai Rd., D'an Dist., Taipei City 106, Taiwan. Upon information and
26 belief, Tanvex BioPharma, Inc. exercises considerable control over the other
27 Defendants with respect to the filing of the TX05 aBLA, development and
28

1 manufacture of TX05, importation of TX05 into the United States, and
2 marketing and distribution of TX05 in California and throughout the United
3 States.

4 7. Upon information and belief, Defendant Tanvex Biologics, Inc. is a
5 corporation organized and existing under the laws of the State of California, with
6 its principal place of business in Irvine, California at 2030 Main Street, #1050,
7 Irvine, CA 92614. Upon information and belief, Tanvex Biologics, Inc.
8 collaborates with each of the other Defendants with respect to the filing of the
9 TX05 aBLA, development and manufacture of TX05, importation of TX05 into
10 the United States, and marketing and distribution of TX05 in California and
11 throughout the United States.

12 8. Upon information and belief, Tanvex Biologics Corporation is a
13 corporation organized and existing under the laws of Taiwan with its principal
14 place of business in New Taipei City 221, Taiwan at 33F, No. 99, Sec. 1, Xintai
15 5th Road, Xizhi District, New Taipei City 221, Taiwan. Upon information and
16 belief, Tanvex Biologics, Inc. collaborates with each of the other Defendants
17 with respect to the filing of the TX05 aBLA, development and manufacture of
18 TX05, importation of TX05 into the United States, and marketing and
19 distribution of TX05 in California and throughout the United States.

20 **JURISDICTION AND VENUE**

21 9. This action arises under the BPCIA, 42 U.S.C. § 262(l), the Patent
22 Laws of the United States, Title 35, United States Code, and the Declaratory
23 Judgment Act, 28 U.S.C. §§ 2201-2202. The Court has subject matter
24 jurisdiction under 28 U.S.C. §§ 1331, 1332, and 1338.

25 10. Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b) and
26 (c), and 28 U.S.C. § 1400(b).

1 11. This Court has personal jurisdiction over each of the Defendants for
2 the reasons set forth below.

3 **A. Tanvex BioPharma USA, Inc.**

4 12. Venue is proper with respect to Tanvex BioPharma USA, Inc.
5 pursuant to 28 U.S.C. § 1400(b) because Tanvex BioPharma USA, Inc. is a
6 corporation organized and existing under the laws of the State of California, with
7 its principal place of business in San Diego, California at 10394 Pacific Center
8 Court, San Diego, CA 92121 and an office in Irvine, California at 2030 Main
9 Street, #1050, Irvine, CA 92614. Upon information and belief, Tanvex
10 BioPharma USA, Inc. develops, manufactures, imports, seeks regulatory
11 approval to market, distribute, and sell biopharmaceuticals for sale and use
12 throughout the United States, including in California and this federal judicial
13 District.

14 13. Personal jurisdiction over Tanvex BioPharma USA, Inc. exists
15 because it is a California corporation with its principal place of business at
16 10394 Pacific Center Court, San Diego, CA 92121.

17 14. Upon information and belief, Tanvex BioPharma USA, Inc.
18 maintains offices and manufacturing facilities at 10421 Pacific Center Court,
19 Suite 100 and San Diego, CA 92121 and 10394 Pacific Center Court, San Diego,
20 CA 92121.

21 15. Moreover, upon information and belief, Tanvex BioPharma USA,
22 Inc., following any FDA approval of the Tanvex TX05 Product, will import,
23 make, and sell the Tanvex TX05 Product in California and throughout the
24 United States.

25 16. Tanvex BioPharma, Inc.'s 2020 Annual Report lists under its
26 "technical operations" that cell culture development, purification, upstream and
27

1 downstream scale up, and commercialization operations are performed by
2 Tanvex BioPharma USA, Inc. *See* Tanvex 2020 Annual Report at 10, Exhibit 4.

3 17. Tanvex BioPharma USA, Inc. is a wholly owned subsidiary of
4 Tanvex BioPharma, Inc., and upon information and belief, Tanvex BioPharma,
5 Inc. exercises considerable control over Tanvex BioPharma USA, Inc.

6 **B. Tanvex BioPharma, Inc.**

7 18. Personal jurisdiction over Tanvex BioPharma, Inc. exists because
8 upon information and belief, Tanvex BioPharma USA, Inc., Tanvex Biologics,
9 Inc., Tanvex BioPharma, Inc., and Tanvex Biologics Corporation hold
10 themselves out as a unitary entity and represent to the public that their activities
11 are directed, controlled, and carried out as a single entity. *See, e.g.*, Tanvex
12 2020 Annual Report at 105, Exhibit 4 (“The Company [Tanvex BioPharma,
13 Inc.] and its subsidiaries (the ‘Group’) are primarily engaged in the research,
14 development, manufacture and sale of biosimilar products. The Group is
15 currently engaged in conducting research and development of biosimilar
16 products, biological production procedures[.]”).

17 19. Personal jurisdiction further exists for Tanvex BioPharma, Inc.
18 because, upon information and belief, Tanvex BioPharma, Inc. exercises control
19 over each of the other Defendants (or at least collaborates with each of the other
20 Defendants) with respect to the filing of the TX05 aBLA, development and
21 manufacture of TX05, importation of TX05 into the United States, and sale,
22 marketing, and distribution of TX05 in California and throughout the United
23 States.

24 20. Upon information and belief, Tanvex BioPharma, Inc. is actively
25 involved with planning Tanvex BioPharma USA, Inc.’s new products and filing
26 the Tanvex aBLA for the proposed biosimilar product in dispute. For example,
27 Tanvex BioPharma, Inc. released a press release about the submission of the
28

1 Tanvex aBLA to the FDA. *See* October 4, 2021 Press Release, FDA Accepts
2 TX05 BLA Filing, Exhibit 5.

3 21. According to Tanvex BioPharma, Inc.’s 2020 Annual Report, there is
4 a 100% overlap between the directors, supervisors, chairman and presidents
5 between Tanvex BioPharma USA, Inc. and Tanvex Biologics Corporation. *See*
6 Tanvex 2020 Annual Report at 88, Exhibit 4.

7 22. According to Tanvex BioPharma, Inc.’s 2020 Annual Report,
8 Tanvex BioPharma, Inc., Tanvex BioPharma USA, Inc., and Tanvex Biologics
9 Corporation have the same CEO and Chairman: Ling-Cheng Chen; these entities
10 further share Allen Chao as a chairman and director. *See* Tanvex 2020 Annual
11 Report at 3 & 88, Exhibit 4.

12 23. Tanvex BioPharma, Inc.’s 2020 Annual Report includes a 2020
13 Statement of Internal Control System, dated March 25, 2021, that identifies five
14 key components of managerial control, including “control activities,”
15 “information and monitoring,” and “communication,” and further states that as
16 of “December 31, 2020, it has maintained in all material respects an effective
17 internal control system (that includes the supervision and management of our
18 subsidiaries).” *See* Tanvex 2020 Annual Report at 46, Exhibit 4.

19 24. Upon information and belief, Defendants Tanvex BioPharma USA,
20 Inc., Tanvex BioPharma, Inc., and Tanvex Biologics Corporation were
21 represented by the same legal counsel in *Amgen Inc. et al. v. Tanvex BioPharma*
22 *USA, Inc. et al.*, No. 19-cv-1374-H-AHG (S.D. Cal.).

23 25. Tanvex BioPharma, Inc.’s 2016 Annual Report lists as a “Material
24 Contract[]” the “Service Agreement” between Tanvex BioPharma USA, Inc.
25 (formerly known as “La Jolla Biologics,” abbreviated as “LJB”) and Tanvex
26 Biologics Corporation under which Tanvex BioPharma USA, Inc. “provides
27
28

1 R&D services to Tanvex Taiwan” (i.e., Tanvex Biologics Corporation). *See*
2 Tanvex 2016 Annual Report, Exhibit 6.

3 26. Tanvex BioPharma, Inc’s 2020 Annual Report lists as a “Material
4 Contract[]” the “Master Collaboration Agreement and SOW” between Tanvex
5 BioPharma USA, Inc. and “Tanvex TW” (i.e., Tanvex Biologics Corporation)
6 for “Collaboration on the biosimilar products development” and which spans
7 from January 1, 2018 to December 31, 2023. *See* Tanvex 2020 Annual Report at
8 71, Exhibit 4. *See also id.* at 7 (stating that in January 2018, La Jolla Biologics,
9 Inc. changed name to Tanvex BioPharma USA, Inc.).

10 27. Upon information and belief, Tanvex BioPharma, Inc.—as
11 evidenced, *inter alia*, by its inter-company agreements, total ownership, overlap
12 of officers and directors, sharing of legal counsel, its website, its press releases,
13 its financial statements, its aBLA materials, and its pervasive, day-to-day control
14 of its subsidiaries—exercises complete dominion over Tanvex BioPharma USA,
15 Inc. and Tanvex Biologics Corporation, rendering them Tanvex BioPharma,
16 Inc.’s alter-ego and/or its agents.

17 28. Upon information and belief, Tanvex BioPharma, Inc. aids, abets,
18 and/or ratifies Tanvex BioPharma USA, Inc. and Tanvex Biologics
19 Corporation’s making, using, and selling of Tanvex’s aBLA Product, TX05—as
20 evidenced, *inter alia*, by its inter-company agreements, total ownership, sharing
21 of legal counsel, its aBLA materials, overlap of officers and directors, its
22 website, its press releases, and its financial statements.

23 29. To the extent Tanvex BioPharma, Inc. is not subject to the
24 jurisdiction of the courts of general jurisdiction of the State of California, it is
25 thus not subject to the jurisdiction of the courts of general jurisdiction of any
26 state, and accordingly is amenable to service of process based on its aggregate
27

1 contacts with the United States, including but not limited to the above-described
2 contacts, as authorized by Rule 4(k)(2) of the Federal Rules of Civil Procedure.

3 30. Venue is proper with respect to Tanvex BioPharma, Inc., a
4 Taiwanese company, pursuant to 28 U.S.C. § 1391(b), (c)(3) and 28 U.S.C. §
5 1400(b). Upon information and belief, Tanvex BioPharma, Inc. collaborates
6 with Tanvex BioPharma USA, Inc., Tanvex Biologics, Inc., and Tanvex
7 Biologics Corporation to develop, manufacture, import into the United States,
8 and seek approval to sell FDA-approved biopharmaceutical drugs, which are to
9 be marketed, distributed, and sold in California and throughout the United
10 States.

11 **C. Tanvex Biologics, Inc.**

12 31. Venue is proper with respect to Tanvex Biologics, Inc., a corporation
13 organized and existing under the laws of the State of California, with its
14 principal place of business in Irvine, California at 2030 Main Street, #1050,
15 Irvine, CA 92614, pursuant to 28 U.S.C. § 1391(b)(2), (c)(2) and 28 U.S.C. §
16 1400(b). Upon information and belief, Tanvex Biologics, Inc. collaborates with
17 Tanvex BioPharma USA, Inc., Tanvex BioPharma, Inc., and Tanvex Biologics
18 Corporation to develop, manufacture, import into the United States, and seek
19 approval to sell FDA-approved biopharmaceutical drugs, which are to be
20 marketed, distributed, and sold in California and throughout the United States.

21 32. Personal jurisdiction over Tanvex Biologics, Inc. exists because it is
22 a California corporation and its principal place of business is at 2030 Main
23 Street, #1050, Irvine, CA 92614.

24 33. Upon information and belief, Tanvex BioPharma USA, Inc., Tanvex
25 Biologics, Inc., Tanvex BioPharma, Inc., and Tanvex Biologics Corporation
26 hold themselves out as a unitary entity and represent to the public that their
27 activities are directed, controlled, and carried out as a single entity. *See, e.g.,*
28

1 Tanvex 2020 Annual Report at 105, Exhibit 4 (“The Company [Tanvex
2 BioPharma, Inc.] and its subsidiaries (the ‘Group’) are primarily engaged in the
3 research, development, manufacture and sale of biosimilar products. The Group
4 is currently engaged in conducting research and development of biosimilar
5 products, biological production procedures[.]”)

6 34. Moreover, upon information and belief, Tanvex Biologics, Inc.,
7 following any FDA approval of the Tanvex TX05 Product, will sell the Tanvex
8 TX05 Product in California and throughout the United States.

9 **D. Tanvex Biologics Corporation**

10 35. Venue is proper with respect to Tanvex Biologics Corporation, a
11 Taiwanese company, pursuant to 28 U.S.C. § 1391(b), (c)(3) and 28 U.S.C. §
12 1400(b). Upon information and belief, Tanvex Biologics Corporation
13 collaborates with Tanvex BioPharma USA, Inc., Tanvex BioPharma, Inc., and
14 Tanvex Biologics, Inc. to develop, manufacture, import into the United States,
15 and seek approval to sell FDA-approved biopharmaceutical drugs, which are
16 intended to be marketed, distributed, and sold in California and throughout the
17 United States.

18 36. Personal jurisdiction over Tanvex Biologics Corporation exists
19 because upon information and belief, Tanvex BioPharma USA, Inc., Tanvex
20 BioPharma, Inc., Tanvex Biologics, Inc., and Tanvex Biologics Corp. hold
21 themselves out as a unitary entity and represent to the public that their activities
22 are directed, controlled, and carried out as a single entity.

23 37. Personal jurisdiction over Tanvex Biologics Corporation further
24 exists because upon information and belief, Tanvex Biologics Corporation
25 collaborates with each of the other Defendants with respect to the filing of the
26 TX05 aBLA, development and manufacture of TX05, importation of TX05 into
27

1 the United States, and marketing and distribution of TX05 in California and
2 throughout the United States.

3 38. Tanvex BioPharma, Inc.’s 2020 Annual Report lists under its
4 “technical operations” that cell line development, cell cultivation, and
5 purification will be performed by Tanvex Biologics Corporation. *See* Tanvex
6 2020 Annual Report at 10, Exhibit 4.

7 39. To the extent Tanvex Biologics Corporation is not subject to the
8 jurisdiction of the courts of general jurisdiction of the State of California, it is
9 thus not subject to the jurisdiction of the courts of general jurisdiction of any
10 state, and accordingly is amenable to service of process based on its aggregate
11 contacts with the United States, including but not limited to the above-described
12 contacts, as authorized by Rule 4(k)(2) of the Federal Rules of Civil Procedure.

13 40. Upon information and belief, Defendants are in agreement—both
14 express and implied—to make, use, and sell TX05.

15 **FACTUAL ALLEGATIONS**

16 **A. Genentech & Herceptin®**

17 41. Genentech was founded in 1976 and for four decades has been at the
18 forefront of innovation in the field of therapeutic biotechnology. Today,
19 Genentech employs a large number of researchers, scientists, and post-doctoral
20 staff members who routinely publish in top peer-reviewed journals and are
21 among the leaders in total citations to their work by researchers. Genentech
22 currently markets numerous approved pharmaceutical and biologic drugs for a
23 range of serious or life-threatening medical conditions, including various forms
24 of cancer, heart attacks, strokes, rheumatoid arthritis, and respiratory diseases.
25 Among these life-saving drugs, Genentech invented its biologic drug,
26 Herceptin®.

1 42. Herceptin® contains a genetically engineered antibody, trastuzumab,
2 which works by attaching to receptors that in large amounts lead to certain
3 cancers, like breast cancer. By attaching to these receptors, trastuzumab stops
4 the cancer cells from growing and dividing. The Food and Drug Administration
5 (“FDA”) approved Herceptin® in 1998. Based on extensive clinical testing by
6 Genentech, Herceptin® is now approved for use in treating breast cancer and
7 gastric cancer. It is one of the top selling medicines in the United States.

8 43. Biologic medicines are complex and complicated to manufacture.
9 Genentech’s innovative work in developing trastuzumab and other antibody
10 drugs has been recognized by the United States Patent and Trademark Office
11 with patents covering the processes for the manufacture of therapeutic
12 antibodies. These issued patents include the three Patents-in-Suit.

13 **B. Tanvex’s aBLA , Manufacture, Importation, and Sale of TX05**

14 44. On August 3, 2021, Tanvex filed aBLA No. 761266 with the FDA
15 seeking approval to market its TX05 product in the United States. On October 4,
16 2021, Tanvex announced that the FDA had accepted its aBLA for review.

17 45. As Tanvex has publicly stated, TX05 is a biosimilar to Herceptin®.
18 *See Exhibit 5, October 4, 2021 Press Release, FDA Accepts TX05 BLA Filing.*
19 Accordingly, under 35 U.S.C. § 271(e)(2)(C), Tanvex has committed a statutory
20 act of patent infringement with respect to patents identified by Genentech under
21 42 U.S.C. § 262(l)(3), through the submission of its aBLA application for TX05.

22 46. Defendants work in concert and/or will work in concert as a single
23 entity to make, use, import, sell, and offer for sale TX05.

24 47. Upon information and belief, Tanvex has and continues to
25 encourage, aid, abet, and/or induce infringement of the Patents-in-Suit of entities
26 involved in making, using, selling, and testing TX05.

1 48. According to Tanvex’s website, attached hereto as Exhibit 7,
2 “[s]train and cell line construction takes place in our Research Lab in Taipei,
3 Taiwan ... Master cell selection and ‘seed’ development also take place in our
4 Taiwan-based facilities ... [And p]rocess and drug product development are
5 carried out in our San Diego, California facility.”

6 49. According to Tanvex’s website, attached hereto as Exhibit 8,
7 manufacturing occurs in Taiwan and its United States facilities, and distribution
8 and sales operations occur at its United States facilities.

9 50. Upon information and belief, Tanvex imports into the United States
10 components of TX05—including but not limited to downstream components of
11 TX05—that are material to the TX05 drug product and substance and are not
12 staple articles. The downstream components of TX05 that are imported by
13 Tanvex into the United States have no substantial non-infringing use besides to
14 be further processed into the TX05 drug product and substance.

15 51. Tanvex filed an aBLA, manufactured, imported, and has and/or plans
16 to distribute and sell TX05 in the United States.

17 52. Upon information and belief, Tanvex encourages, aids, abets, and/or
18 induces third parties to partake in the commercial manufacture of TX05, use
19 TX05, and/or sell or offer for sale TX05 in the United States.

20 **C. The Parties’ Exchanges Under the BPCIA**

21 53. On October 4, 2021, Tanvex announced that the FDA had accepted
22 its aBLA No. 761266 for review.

23 54. On October 27, 2021, Tanvex provided Genentech with a copy of its
24 aBLA. By providing its aBLA only, Tanvex did not provide all of
25 manufacturing information for TX05 required by 42 U.S.C. § 262(l)(2)(A).

26 55. On November 12, 2021, Genentech responded by identifying
27 deficiencies in Tanvex’s production of manufacturing information and
28

1 requesting specific information concerning the manufacturing of Tanvex’s
2 biosimilar product. Genentech further explained that Tanvex’s production was
3 deficient because it failed to provide all of the requested information in
4 contravention of 42 U.S.C. § 262(l)(2).

5 56. Tanvex did not correct these deficiencies, and did not disclose all the
6 information relevant to establishing whether the manufacture of Tanvex’s aBLA
7 product will infringe each of the patents identified on Genentech’s operative list
8 pursuant to 42 U.S.C. § 262(l)(3)(A).

9 57. Despite Tanvex’s non-compliance (and without waiving Genentech’s
10 objection to such non-compliance), Genentech provided its operative list of
11 seven patents pursuant to 42 U.S.C. § 262(l)(3)(A) on December 24, 2021.
12 Tanvex’s failure to provide sufficient information under those circumstances
13 justifies Genentech’s contention that manufacturing Tanvex’s aBLA product
14 will infringe such patents.

15 58. On February 22, 2022, Tanvex purported to provide its detailed
16 statement concerning non-infringement and invalidity pursuant to 42 U.S.C. §
17 262(l)(3)(B) (“Tanvex’s 3B Statement”). Tanvex’s 3B Statement was deficient
18 in numerous ways. For example, it—like Tanvex’s document productions—
19 failed to fully describe Tanvex’s manufacturing process, such that Genentech
20 was unable to evaluate many of Tanvex’s non-infringement arguments.
21 Tanvex’s 3B Statement also failed to provide any statements of invalidity
22 pursuant to 42 U.S.C. § 262(l)(3)(B) for any of the patents on Genentech’s 3A
23 list.

24 59. On April 21, 2022, and subject to its objections, Genentech provided
25 its response pursuant to 42 U.S.C. § 262(l)(3)(C) (“Genentech’s 3C Statement”)
26 and stated that Tanvex’s vague incorporation of indiscriminate arguments and
27 legal concepts was insufficient under 42 U.S.C. § 262(l)(3)(B), and that it further
28

1 thwarted Genentech’s ability to respond. Genentech also stated that “[w]here
2 Tanvex could have, but did not, provide the required detailed statement on
3 invalidity, Tanvex has waived any invalidity arguments in future litigation or in
4 an administrative proceeding based on information that was available when
5 Tanvex served its contentions.”¹

6 60. Genentech’s 3C Statement included responses to Tanvex’s non-
7 infringement statements and addressed Tanvex’s failure to identify invalidity
8 positions for each of the patents addressed in its 3B Statement and maintained
9 that TX05 will infringe at least three Genentech patents, the Patents-in-Suit.
10 With its 3C Statement, Genentech proposed that Tanvex agree that all three of
11 these patents be included in a first-phase infringement action under § 262(l)(6).

12 61. After Genentech served its 3C Statement, Tanvex sent
13 correspondence on May 3, 2022 that it agreed that the Patents-in-Suit should be
14 included in an infringement action.

15 62. In light of the parties’ agreement, § 262(l)(6)(A) required Genentech
16 to bring an action for patent infringement with respect to each of the three
17 patents that were part of the parties’ agreement. This action is Genentech’s
18 action pursuant to § 262(l)(6)(A), and is brought within 30 days of the parties’
19 Tanvex’s May 3, 2022 letter.

20 **D. Genentech’s Patents-in-Suit**

21 63. Upon information and belief, Tanvex’s aBLA product will infringe at
22 least the following patents, which Genentech asserts in this lawsuit the Patents-
23 in-Suit: U.S. Patent No. 10,662,237, U.S. Patent No. 10,808,037, U.S. Patent
24 No. 8,574,869. The Patents-in-Suit claim novel techniques developed by
25 Genentech relating to various aspects of cell culture and antibody purification.

26 _____
27 ¹ To the extent Tanvex has not waived its invalidity arguments, Genentech’s 3C
28 Statement stated that it reserved its right to respond to such challenges on the
merits at that time.

1 64. U.S. Patent No. 10,662,237 (“the ’237 patent”), titled “Method to
2 Improve Virus Filtration Capacity,” was duly and legally issued by the Patent
3 Office on May 26, 2020. A true and correct copy of the ’237 patent is attached
4 as Exhibit 1. Genentech is the owner by assignment of the ’237 patent.
5 The ’237 patent claims methods of viral filtration used in the manufacture of a
6 biological product.

7 65. U.S. Patent No. 10,808,037 (“the ’037 patent”), titled “Prevention of
8 Disulfide Bond Reduction During Recombinant Production of Polypeptides,”
9 was duly and legally issued by the Patent Office on October 20, 2020. A true
10 and correct copy of the ’037 patent is attached as Exhibit 2. Genentech is the
11 owner by assignment of the ’037 patent. The ’037 patent claim methods of
12 reducing certain molecular bonds in recombinant proteins used in the
13 manufacture of a biological product.

14 66. U.S. Patent No. 8,574,869 (“the ’869 patent”), titled “Prevention of
15 Disulfide Bond Reduction During Recombinant Production of Polypeptides,”
16 was duly and legally issued by the Patent Office on November 5, 2013. A true
17 and correct copy of the ’869 patent is attached as Exhibit 3. Genentech is the
18 owner by assignment of the ’869 patent. The ’869 patent claim methods of
19 reducing certain molecular bonds in recombinant proteins used in the
20 manufacture of a biological product.

21 **FIRST CLAIM FOR RELIEF**

22 **(INFRINGEMENT OF THE ’237 PATENT)**

23 67. Genentech incorporates by reference paragraphs 1-66 as if fully set
24 forth therein.

25 68. Upon review of publicly available information and/or information
26 provided by Tanvex pursuant to 42 U.S.C. § 262(l)(2), Genentech believes that a
27 claim of patent infringement, either literally or under the doctrine of equivalents,
28

1 could reasonably be asserted by Genentech if a person not licensed by
2 Genentech engaged in the making, using, offering to sell, selling, or importing
3 into the United States of TX05 prior to the expiration of the '237 patent.
4 Genentech included the '237 patent in its disclosure of patents pursuant to 42
5 U.S.C. § 262(l)(3)(A). Genentech also provided Tanvex with a detailed
6 statement that describes, on a claim-by-claim basis, the factual and legal basis of
7 its belief that at least claims 1-22 of the '237 patent will be infringed by the
8 commercial marketing of TX05, pursuant to 42 U.S.C. § 262(l)(3)(C).

9 69. Tanvex submitted its aBLA to obtain approval to engage in the
10 commercial manufacture, use, or sale of TX05 before the expiration of the '237
11 patent. Tanvex has therefore committed a technical act of infringement of one
12 or more claims of the '237 patent under 35 U.S.C. § 271(e)(2)(C)(i).

13 70. Likewise, based on publicly available information and/or information
14 provided by Tanvex pursuant to 42 U.S.C. § 262(l)(2), Genentech reasonably
15 believes that Tanvex will infringe at least claims 1-22 of the '237 patent in
16 violation of 35 U.S.C. §§ 271(a), (b), (c), and/or (g) as a result of its activities
17 relating to the manufacture, importation, sale, offer for sale, use, and promotion
18 of the use of the TX05 drug substance and its proposed TX05 product, as
19 explained in Genentech's 3C Statement.

20 71. Representative Claim 1 of the '237 patent recites:

21 A method of virus filtration comprising subjecting a
22 composition comprising

23 a recombinant protein produced in a mammalian
24 host cell and having or suspected of having a
25 parvovirus contaminant

26 to a virus filtration process comprising a cation
27 exchange step and an endotoxin removal step,
28 simultaneously or in either order, immediately

1 preceding a virus filter capable of removing a
2 parvovirus,

3 and wherein said virus filter's filtration capacity in
4 kg/m² is improved between 1.5 to 20 fold, as
5 compared to no prefiltration step or using either
6 cation exchange step or endotoxin removal step
alone.

7 72. Upon information and belief as set forth in Tanvex's detailed
8 statement pursuant to 42 U.S.C. § 262(l)(3)(C) that relies on the confidential
9 information that Tanvex was willing to provide to Genentech pursuant to 42
10 U.S.C. § 262(l)(2), the process by which Defendants manufacture and/or seek to
11 manufacture the Tanvex TX05 Product satisfies each limitation of at least claims
12 1-22 of the '237 patent, literally or under the doctrine of equivalents.
13 Defendants practice a method of virus filtration of the recombinant protein
14 TX05, suspected of having parvovirus contamination, wherein they employ a
15 cation exchange step and an endotoxin removal step—simultaneously and/or in
16 either order—immediately preceding a filter capable of removing parvovirus; the
17 result of this method of virus filtration is a 1.5 to 20 fold improved capacity in
18 kg/m² as compared to no prefiltration or using the cation or endotoxin steps
19 alone. Each of these claim elements is met literally or equivalently in
20 Defendants' process.

21 73. Pursuant to 28 U.S.C. § 2201, Genentech is entitled to a declaratory
22 judgment that Tanvex's manufacture, importation, sale, offer for sale, use, and
23 promotion of the use of the TX05 drug substance and Tanvex's proposed TX05
24 drug product will infringe the '237 patent pursuant to 35 U.S.C. §§ 271(a), (b),
25 (c), and/or (g).

26 74. Tanvex has knowledge of and is aware of the '237 patent, including
27 due to Genentech's disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A)
28

1 and the filing of this Complaint. Tanvex's infringement of the '237 patent is
2 willful.

3 75. To the extent Defendants commercialize their product prior to the
4 expiration of the '237 patent, Genentech will also be entitled to damages under
5 35 U.S.C. § 284.

6 76. The manufacture, use, offer for sale, or sale within the United States,
7 or importation into the United States, of the Tanvex TX05 product before the
8 expiration of the '237 patent will cause injury to Genentech, entitling it to
9 damages or other monetary relief under 35 U.S.C. § 271(e)(4)(C).

10 **SECOND CLAIM FOR RELIEF**
11 **(INFRINGEMENT OF THE '037 PATENT)**

12 77. Genentech incorporates by reference paragraphs 1-66 as if fully set
13 forth therein.

14 78. Upon review of publicly available information and/or information
15 provided by Tanvex pursuant to 42 U.S.C. § 262(l)(2), Genentech believes that a
16 claim of patent infringement, either literally or under the doctrine of equivalents,
17 could reasonably be asserted by Genentech if a person not licensed by
18 Genentech engaged in the making, using, offering to sell, selling, or importing
19 into the United States of TX05 prior to the expiration of the '037 patent.
20 Genentech included the '037 patent in its disclosure of patents pursuant to 42
21 U.S.C. § 262(l)(3)(A). Genentech also provided Tanvex with a detailed
22 statement that describes, on a claim-by-claim basis, the factual and legal basis of
23 its belief that at least claims 1, 3, and 5-9 of the '037 patent will be infringed by
24 the commercial marketing of TX05, pursuant to 42 U.S.C. § 262(l)(3)(C).

25 79. Tanvex submitted its aBLA to obtain approval to engage in the
26 commercial manufacture, use, or sale of TX05 before the expiration of the '037
27

1 patent. Tanvex has therefore committed a technical act of infringement of one
2 or more claims of the '037 patent under 35 U.S.C. § 271(e)(2)(C)(i).

3 80. Likewise, based on publicly available information and/or information
4 provided by Tanvex pursuant to 42 U.S.C. § 262(l)(2), Genentech reasonably
5 believes that Tanvex will infringe at least claims 1, 3, and 5-9 of the '037 patent
6 in violation of 35 U.S.C. §§ 271(a), (b), (c) and/or (g) as a result of its activities
7 relating to the manufacture, importation, sale, offer for sale, use, and promotion
8 of the use of the TX05 drug substance and its proposed TX05 product, as
9 explained in Genentech's 3C Statement.

10 81. Representative Claim 1 of the '037 patent recites:

11 A method for producing an antibody, comprising

12 expressing the antibody in a Chinese Hamster
13 Ovary (CHO) recombinant host cell culture,

14 and following a production phase of the cell
15 culture,

16 sparging the pre-harvest cell culture fluid of the
17 recombinant host cell with air to inhibit reduction
18 of a disulfide bond in the antibody during
19 processing,

20 wherein the antibody is a therapeutic monoclonal
21 antibody that binds to human epidermal growth
22 factor receptor 2 (HER2),

23 and wherein the air sparging is continued until the
24 amount of dissolved oxygen (dO₂) in the pre-
25 harvest cell culture fluid is at least 10%.

26 82. Upon information and belief as set forth in Tanvex's detailed
27 statement pursuant to 42 U.S.C. § 262(l)(3)(C) that relies on the confidential
28 information that Tanvex was willing to provide to Genentech pursuant to 42
U.S.C. § 262(l)(2), the process by which Defendants manufacture and/or seek to

1 manufacture the Tanvex TX05 Product satisfies each limitation of at least claims
2 1-22 of the '037 patent, literally or under the doctrine of equivalents.

3 Defendants practice a method of producing the antibody TX05 (trastuzumab),
4 expressed through a Chinese Hamster Ovary (CHO) recombinant host cell;
5 following a production phase of the cell culture in which TX05 is expressed,
6 Defendants inhibit reduction in disulfide bonds in TX05 by sparging the pre-
7 harvest cell culture fluid of the recombinant host cell with air; Defendants
8 continue that sparging until the amount of dissolved oxygen is at least of 10% to
9 30%. Each of these claim elements is met literally or equivalently in
10 Defendants' process.

11 83. Pursuant to 42 U.S.C. § 262(l)(9)(A) and 28 U.S.C. § 2201,
12 Genentech is entitled to a declaratory judgment that Tanvex's manufacture,
13 importation, sale, offer for sale, use, and promotion of the use of the TX05 drug
14 substance and Tanvex's proposed TX05 drug product will infringe the '037
15 patent pursuant to 35 U.S.C. §§ 271(a), (b), (c) and/or (g).

16 84. Tanvex has knowledge of and is aware of the '037 patent, including
17 due to Genentech's disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A)
18 and the filing of this Complaint. Tanvex's infringement of the '037 patent is
19 willful.

20 85. To the extent Defendants commercialize their product prior to the
21 expiration of the '037 patent, Genentech will also be entitled to damages under
22 35 U.S.C. § 284.

23 86. The manufacture, use, offer for sale, or sale within the United States,
24 or importation into the United States, of the Tanvex TX05 product before the
25 expiration of the '037 patent will cause injury to Genentech, entitling it to
26 damages or other monetary relief under 35 U.S.C. § 271(e)(4)(C).

THIRD CLAIM FOR RELIEF
(INFRINGEMENT OF THE '869 PATENT)

87. Genentech incorporates by reference paragraphs 1-66 as if fully set forth therein.

88. Upon review of publicly available information and/or information provided by Tanvex pursuant to 42 U.S.C. § 262(l)(2), Genentech believes that a claim of patent infringement, either literally or under the doctrine of equivalents, could reasonably be asserted by Genentech if a person not licensed by Genentech engaged in the making, using, offering to sell, selling, or importing into the United States of TX05 prior to the expiration of the '869 patent. Genentech included the '869 patent in its disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A). Genentech also provided Tanvex with a detailed statement that describes, on a claim-by-claim basis, the factual and legal basis of its belief that at least claims 1, 4-5, and 7-8 of the '869 patent will be infringed by the commercial marketing of TX05, pursuant to 42 U.S.C. § 262(l)(3)(C).

89. Tanvex submitted its aBLA to obtain approval to engage in the commercial manufacture, use, or sale of TX05 before the expiration of the '869 patent. Tanvex has therefore committed a technical act of infringement of one or more claims of the '869 patent under 35 U.S.C. § 271(e)(2)(C)(i).

90. Likewise, based on publicly available information and/or information provided by Tanvex pursuant to 42 U.S.C. § 262(l)(2), Genentech reasonably believes that Tanvex will infringe at least claims 1, 4-5, and 7-8 of the '869 patent in violation of 35 U.S.C. §§ 271(a), (b), (c), and/or (g) as a result of its activities relating to the manufacture, importation, sale, offer for sale, use, and promotion of the use of the TX05 drug substance and its proposed TX05 product, as explained in Genentech's 3C Statement.

91. Representative Claim 1 of the '869 patent recites:

1 A method for the prevention of the reduction of a disulfide
2 bond in an antibody expressed in a recombinant host cell,
3 comprising,

4 following fermentation,

5 sparging the pre-harvest or harvested culture fluid
6 of said recombinant host cell with air,

7 wherein the amount of dissolved oxygen (dO₂) in
8 the pre-harvest or harvested culture fluid is at least
9 10%.

9 92. Upon information and belief as set forth in Tanvex's detailed
10 statement pursuant to 42 U.S.C. § 262(l)(3)(C) that relies on the confidential
11 information that Tanvex was willing to provide to Genentech pursuant to 42
12 U.S.C. § 262(l)(2), the process by which Defendants manufacture and/or seek to
13 manufacture the Tanvex TX05 Product satisfies each limitation of at least claims
14 1-22 of the '869 patent, literally or under the doctrine of equivalents.
15 Defendants practice a method of preventing the reduction of a disulfide bond in
16 is antibody TX05 trastuzumab product, which is expressed in a recombinant host
17 cell; Defendants prevent the reduction of a disulfide bond following
18 fermentation by sparging with air the pre-harvest culture fluid of the
19 recombinant host cell; Defendants sparge the pre-harvest culture fluid with air
20 until the amount of dissolved oxygen is at least 10% to 30%. Each of these
21 claim elements is met literally or equivalently in Defendants' process.

22 93. Pursuant to 28 U.S.C. § 2201, Genentech is entitled to a declaratory
23 judgment that Tanvex's manufacture, importation, sale, offer for sale, use, and
24 promotion of the use of the TX05 drug substance and Tanvex's proposed TX05
25 drug product will infringe at least claims 1, 4-5, and 7-8 of the '869 patent
26 pursuant to 35 U.S.C. §§ 271(a), (b), (c), and/or (g).

1 94. Tanvex has knowledge of and is aware of the '869 patent, including
2 due to Genentech's disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A)
3 and the filing of this Complaint. Tanvex's infringement of the '869 patent is
4 willful.

5 95. To the extent Defendants commercialize their product prior to the
6 expiration of the '869 patent, Genentech will also be entitled to damages under
7 35 U.S.C. § 284.

8 96. The manufacture, use, offer for sale, or sale within the United States,
9 or importation into the United States, of the Tanvex TX05 product before the
10 expiration of the '869 patent will cause injury to Genentech, entitling it to
11 damages or other monetary relief under 35 U.S.C. § 271(e)(4)(C).

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 **PRAYER FOR RELIEF**

2 Wherefore, Genentech respectfully request that this Court enter judgment
3 in its favor against Tanvex and grant the following relief:

- 4 1. a judgment that Tanvex has infringed directly, by divided
5 infringement, or contributorily or induced infringement of one or
6 more claims of the asserted patents under 35 U.S.C. § 271(e)(2)(C);
- 7 2. a judgment that Tanvex has infringed or will infringe directly, by
8 divided infringement, or contributorily, or has induced or will
9 induce infringement, of one or more claims of the asserted patents
10 by engaging in the manufacture, import, offer for sale, sale, or use
11 within the United States of the Tanvex aBLA product before the
12 expirations of the asserted patents under 35 U.S.C. §§ 271(a), (b),
13 (c), and/or (g);
- 14 3. monetary damages in the event that Tanvex imports, manufactures,
15 or launches its biosimilar product and/or otherwise practices the
16 patented inventions in the United States prior to the expiration of the
17 asserted patents, including lost profits and/or a reasonable royalty,
18 and an accounting and/or ongoing royalty for any post-judgment
19 infringement;
- 20 4. a judgment that Tanvex’s infringement was willful and
21 enhancement of any monetary damages pursuant to 35 U.S.C. § 284;
- 22 5. a declaration that this is an exceptional case and an award to
23 Genentech of its attorneys’ fees, costs, and expenses pursuant to 35
24 U.S.C. § 271(e)(4) and 35 U.S.C. § 285; and
- 25 6. such other relief as this Court may deem just and proper.
- 26
27
28

1 **JURY TRIAL DEMAND**

2 Genentech hereby demands a jury trial pursuant to Rule 38 of the Federal
3 Rules of Civil Procedure as to all issues so triable.

4
5 Dated: June 2, 2022

WILMER CUTLER PICKERING HALE AND
DORR LLP

6
7 By: /s/ Jason Choy

Jason Choy
Jason.Choy@wilmerhale.com
WILMER CUTLER PICKERING
HALE AND DORR LLP
350 South Grand Avenue, Suite 2400
Los Angeles, CA 90071
Telephone: +1 213 443 5334
Facsimile: +1 213 443 5400

8
9
10
11
12 Robert J. Gunther Jr.
(*pro hac vice to be filed*)
Robert.Gunther@wilmerhale.com
WILMER CUTLER PICKERING
HALE AND DORR LLP
7 World Trade Center
250 Greenwich Street
New York, NY 10007
Telephone: +1 212 230 8830
Facsimile: +1 212 230 8888

13
14
15
16
17 *Attorneys for Plaintiff*